New cancer vax shows promise among late-stage victims

With support from the National Cancer Institute and Alphavax, researchers say that a new oncology vaccine has triggered a significant immune response among a group of patients suffering from a range of cancers. The group, which was led by Duke University's Dr. Michael Morse, used an alphavirus-which are known to target dendritic cells-to precisely deliver a gene for the carcinoembryonic antigen, a common biomarker in cancer. And they tested it on 28 patients with late-stage lung, colon, breast,...